Biogen’s New Boss Is Delivering, but Stock Isn’t Pricing It in Yet

[ad_1]

The decision to buy Reata signals a new era under CEO Chris Viehbacher, and Wall Street’s skepticism presents an opportunity.

[ad_2]

Source link